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Abstract
Background: Systemic antibiotics vary widely in in vitro activity against Clostridium difficile. Some agents with
activity against C. difficile (e.g., piperacillin/tazobactam) inhibit establishment of colonization in mice. We tested
the hypothesis that piperacillin/tazobactam and other agents with activity against C. difficile achieve sufficient
concentrations in the intestinal tract to inhibit colonization in patients.
Methods: Point-prevalence culture surveys were conducted to compare the frequency of asymptomatic rectal
carriage of toxigenic C. difficile among patients receiving piperacillin/tazobactam or other inhibitory antibiotics
(e.g. ampicillin, linezolid, carbapenems) versus antibiotics lacking activity against C. difficile (e.g., cephalosporins,
ciprofloxacin). For a subset of patients, in vitro inhibition of C. difficile (defined as a reduction in concentration after
inoculation of vegetative C. difficile into fresh stool suspensions) was compared among antibiotic treatment groups.
Results: Of 250 patients, 32 (13 %) were asymptomatic carriers of C. difficile. In comparison to patients receiving
non-inhibitory antibiotics or prior antibiotics within 90 days, patients currently receiving piperacillin/tazobactam
were less likely to be asymptomatic carriers (1/36, 3 versus 7/36, 19 and 15/69, 22 %, respectively; P = 0.024) and
more likely to have fecal suspensions with in vitro inhibitory activity against C. difficile (20/28, 71 versus 3/11, 27
and 4/26, 15 %; P = 0.03). Patients receiving other inhibitory antibiotics were not less likely to be asymptomatic
carriers than those receiving non-inhibitory antibiotics.
Conclusions: Our findings suggest that piperacillin/tazobactam achieves sufficient concentrations in the intestinal
tract to inhibit C. difficile colonization during therapy.
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Background
Antimicrobial exposure is the most important risk factor
for Clostridium difficile infection (CDI) [1]. Clindamycin,
third-generation cephalosporins, and fluoroquinolones
are generally considered the agents that pose the great-
est risk [1]. Restriction of these high-risk antibiotics may
be a useful strategy to control CDI, but there is
uncertainty regarding the selection of alternative agents
that might have a lower propensity to cause CDI. Several
recent studies have suggested that antibiotics with inhibi-
tory activity against C. difficile (e.g., piperacillin/tazobactam,
tigecycline, doxycycline, linezolid,) may pose a relatively
low risk for CDI [2–7]. Moreover, Dubberke et al. [7] re-
cently reported that cephalosporin use was associated with
acquisition of C. difficile colonization, whereas β-lactam-β-
lactamase inhibitor combinations and metronidazole use
were associated with loss of colonization. Substitution of pi-
peracillin/tazobactam for third-generation cephalosporins
has been associated with reductions in the incidence of
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CDI [2, 3]. Similarly, substitution of piperacillin/tazobactam
for cephalosporins has been associated with reductions in
colonization with vancomycin-resistant enterococci (VRE)
and extended-spectrum beta-lactamase-producing Entero-
bacteriacae [8, 9]. In mice, piperacillin/tazobactam and tige-
cycline inhibited acquisition of C. difficile colonization
during treatment [10, 11]. However, it is not known if these
agents achieve sufficient concentrations in the intestinal
tract to inhibit C. difficile colonization in patients. In fact,
Wilcox et al. [12] and Nord et al. [13] found significant
inter-patient variability in excretion of piperacillin and tazo-
bactam in stool of patients.
One primary objective of this study was to test the hy-
pothesis that antibiotics with inhibitory activity against
C. difficile are infrequently associated with C. difficile
colonization during treatment in hospitalized patients. A
second primary objective was to determine if antibiotics
with in vitro inhibitory activity against C. difficile achieve
sufficient concentrations in stool to inhibit in vitro
growth of C. difficile. Our analysis focused primarily on
piperacillin/tazobactam because it is the most commonly
used broad-spectrum agent in our facility.
Methods
Ethics statement
The Cleveland VA Medical Center’s Institutional Review
Board approved the study protocol. All subjects provided
verbal informed consent for specimen collection and
medical record review.
Setting and participants
The Cleveland Veterans Affairs Medical Center is a 215-
bed acute care hospital. During a 1-year period, intermit-
tent point-prevalence culture surveys for asymptomatic
carriage of toxigenic C. difficile were collected from con-
senting inpatients with no symptoms of CDI on 7 wards,
including 3 medical wards, 1 surgical ward, a geriatric
rehabilitation ward, a surgical intensive care unit, and a
medical intensive care unit. The incidence of CDI was 7
cases per 10,000 patient-days during the study period
with no outbreaks or clusters of CDI. Medical record
review was conducted to obtain information on demo-
graphics, medical conditions, previous CDI, length of
stay, antibiotic and subsequent development of CDI in
the next 90 days. Based upon a modification of the clas-
sification scheme of Owens et al. [1], antibiotics on the
formulary were classified as having inhibitory activity
against C. difficile that was moderate to good (i.e., ampicil-
lin, amoxicillin, linezolid, metronidazole, imipenem, mero-
penem, piperacillin/tazobactam, tigecycline, tetracyclines)
or poor (i.e., cephalosporins, ciprofloxacin, and trimetho-
prim/sulfamethoxazole). Intravenous vancomycin was not
classified as inhibitory because it achieves relatively low
levels in the intestinal tract [14]. Moxifloxacin was
classified as having variable activity against C. difficile
because we have previously shown that isolates from our
facility have variable susceptibility to moxifloxacin [15].
For patients receiving multiple antibiotics concurrently,
the regimen was classified as inhibitory if one agent had
moderate to good inhibitory activity.
Microbiological methods
Peri-rectal swabs or fresh stool specimens were collected
and transferred to an anaerobic chamber (Coy Labora-
tories, Grass Lake, MI). Swabs or aliquots of stool were
plated directly onto pre-reduced C. difficile Brucella
Agar containing taurocholic acid and lysozyme (CDBA-
TAL) and incubated for 48 h [16]. In addition, to evalu-
ate the possibility that carry over of antibiotics in stool
to culture plates might result in false-negative cultures,
all stool samples were serially diluted in phosphate-
buffered saline to dilute any residual antibiotic and the
dilutions were plated onto CDBA-TAL. Isolates were
confirmed to be C. difficile on the basis of typical odor
and appearance of colonies and by a positive reaction
using C. difficile latex agglutination (Microgen Biopro-
ducts, Camberly, UK). All C. difficile isolates were tested
for in-vitro cytotoxin production using C. difficile Tox
A/B II (Wampole Laboratories, Princeton, NJ), and iso-
lates that did not produce toxin were excluded from the
analysis.
In vitro assay for inhibitory activity in fecal suspensions
To assess whether inhibitory concentrations of antibi-
otics were present in stool, a subset of patients whose
fresh stool specimens were available after a minimum of
24 h of antibiotic treatment, were tested using a modifi-
cation of the in vitro assay of colonization resistance
developed by Borriello and Barclay [17]. To determine if
inhibitory activity persisted after discontinuation of anti-
biotics, stool specimens collected up to 2 weeks after
discontinuation of antibiotics were also analyzed. Up to
3 stool samples were analyzed per patient. The test
strain was an epidemic NAP1/027/BI strain (VA 17).
The minimum inhibitory concentrations (MICs) of sev-
eral commonly used antibiotics for VA 17 are shown in
Table 1. Fresh stool samples were homogenized in a 1:1
dilution of pre-reduced sterile water and inoculated with
104 colony-forming units (CFU) per mL of vegetative C.
difficile inside the anaerobic chamber. Serially-diluted
samples were plated onto CDBA plates to determine the
concentration of C. difficile immediately after inocula-
tion and after incubation at 37 °C for 24 h. Samples with
detectable levels of C. difficile prior to the inoculation of
vegetative C. difficile were excluded. Specimens were
considered inhibitory if the concentration of C. difficile
decreased or remained unchanged compared to the
baseline concentration. Inhibition of the C. difficile
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isolates was concurrently assessed in sterile filtrates of the
stool suspensions. The filtrates were produced by centrifu-
ging the suspensions at 10,000 rpm for 10 min, followed
by filtering the supernatant through a 0.22 μm filter.
Statistical analysis
The frequency of asymptomatic carriage was com-
pared for patients receiving piperacillin/tazobactam-
containing or other inhibitory regimens versus those
receiving non-inhibitory antibiotic regimens and/or
prior antibiotics in the past 90 days. Log-binomial re-
gression with robust variance estimation was used to
model predictors of asymptomatic C. difficile carriage
[18]. This approach yields a prevalence ratio with
95 % confidence intervals. Student t- and Wilcoxon
rank sum tests were used for normally and non-
normally distributed data, respectively. Fisher’s exact
test was used to compare the proportions of stool
suspensions that were inhibitory to growth of C. diffi-
cile. Data were analyzed with the use of SAS statis-
tical software, version 9.1 (SAS Institute) and STATA
11 (StataCorp, College Station, TX).
Results
Frequency of and risk factors for asymptomatic carriage
of C. difficile
Of 250 patients screened, 32 (13 %) were asymptomatic
carriers of C. difficile and 218 were non-carriers. There
was no evidence of clustering of colonized patients
on specific wards (range, 2 to 7 colonized patients on
each ward). As shown in Table 2, by bivariate analysis
carriers were significantly more likely to have prior
CDI or antibiotic treatment within 90 days. However,
current antibiotic treatment was not associated with
asymptomatic carriage. The length of stay at the time of
culture collection was higher in those with asymptomatic
carriage, but the difference was not statistically significant.
Table 1 Minimum Inhibitory Concentrations (MICs) of















aMICs were determined by broth dilution. The test strain (VA 17) is an
epidemic NAP1/027/BI strain
Table 2 Characteristics of 32 Asymptomatic Carriers of Clostridium difficile and 218 Non-carriers
Characteristic All participants (N = 250) Asymptomatic carriers (N = 32) Non-carriers (N = 218) P value
Mean (SD) age (years) 66.9 (11.9) 64.3 (12.1) 67.2 (11.8) 0.19
Median (IQR) days from admission to culture 9 (4, 15) 11.5 (6, 20.5) 8 (4, 14) 0.07
Days from admission to culture
0–7 110 13 (41) 97 (44) 0.34
8–14 75 7 (22) 68 (31)
15–21 27 4 (12) 23 (11)
≥22 38 8 (25) 30 (14)
CDI in the previous 90 days 13 6 (19) 7 (3) <0.001
Antibiotics in the past 90 days 155 27 (84) 128 (59) 0.005
Antibiotics in the past 30 days 144 24 (75) 120 (55) 0.03
Current antibiotic treatment 98 12 (38) 86 (39) 0.83
Comorbidities
Heart disease 95 9 (28) 86 (39) 0.22
Cancer 85 12 (37) 73 (33) 0.65
Diabetes 103 11 (34) 92 (42) 0.40
End stage renal disease 23 3 (9) 20 (9) 0.97
Major surgery 70 8 (25) 62 (28) 0.69
Spinal cord injury 21 4 (13) 17 (8) 0.32
Data are no. (%) of patients, unless otherwise specified. SD standard deviation, IQR interquartile range
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Four of the asymptomatic carriers subsequently developed
CDI, including 3 episodes of recurrent CDI and 1 initial
episode.
Antibiotic therapy and C. difficile colonization
Figure 1 shows a comparison of the frequency of asymp-
tomatic carriage of C. difficile, stratified by antibiotic
treatment category. In comparison to patients receiving
non-inhibitory antibiotics or prior antibiotics within
90 days, patients receiving current piperacillin/tazobac-
tam were significantly less likely to be carriers of C. diffi-
cile (3 versus 18 and 22 %, respectively; P ≤ 0.02). Six of
the 14 (43 %) patients with C. difficile carriage who had
received prior antibiotics within 90 days had received
regimens that included piperacillin/tazobactam. For the
6 patients who had received prior piperacillin/tazobac-
tam, the mean number of days since the last dose of
piperacillin/tazobactam was 7.5 (range, 2 to 14 days); for
the 8 patients who received prior antibiotics other than
piperacillin/tazobactam, the mean number of days since
the last dose of antibiotics was 7.1 (range, 1 to 21 days).
Patients receiving other inhibitory antibiotics were not
less likely to be asymptomatic carriers than those receiv-
ing non-inhibitory antibiotics. Patients who had not
received antibiotic therapy within the past 90 days were
infrequently colonized with C. difficile.
Table 3 shows prevalence ratios of predictors of
asymptomatic carriage generated using log-binomial
regression analysis. Prior CDI and antibiotic use
within 90 days were significant predictors of asymp-
tomatic carriage, whereas current piperacillin/tazobac-
tam use was protective in comparison to current
non-inhibitory antibiotic use and/or antibiotic use in
the past 90 days (P = 0.051).
In vitro inhibitory activity of fecal suspensions
Figure 2 provides a comparison of the proportions of
fecal suspensions that were inhibitory to in vitro growth
of C. difficile strain VA 17 and the mean (+/− standard
error) change in C. difficile concentration, stratified by
the type of antibiotic treatment. One-hundred forty-one
stool specimens collected from 98 total patients were
analyzed (1–3 per patient). In comparison to suspen-
sions from patients on non-inhibitory antibiotics or with
prior antibiotic exposure within 90 days, current pipera-
cillin/tazobactam therapy was associated with more fre-
quent inhibition of C. difficile growth (71 versus 27 and
44 %, respectively; P = 0.03). In contrast, only 30 % of
stool suspensions from patients with prior rather than
current piperacillin/tazobactam therapy were inhibitory
to C. difficile growth; the time of collection of the speci-
mens after discontinuation of piperacillin/tazobactam
ranged from 1 to 7 days. Suspensions from patients on
other inhibitory antibiotics were associated with more
frequent inhibition in comparison to suspensions from
patients with prior antibiotic exposure (P = 0.004), but
not in comparison to suspensions from patients on non-
inhibitory antibiotics (P = 0.14). Suspensions from
patients on moxifloxacin were not associated with more
frequent inhibition than suspensions from patients with
prior antibiotic exposure or on non-inhibitory antibiotics
(P = 0.07).
Of the 28 stool specimens analyzed during current
piperacillin/tazobactam therapy, 10 (36 %) were from
Fig. 1 Frequency of asymptomatic carriage of toxigenic Clostridium difficile in hospitalized patients, stratified by antibiotic treatment classification.
Based upon a modification of the classification scheme of Owens et al. [1], antibiotics on the formulary that were classified as having inhibitory
activity against C. difficile included ampicillin, amoxicillin, linezolid, metronidazole, imipenem, meropenem, piperacillin/tazobactam, tigecycline,
and tetracyclines. Antibiotics on the formulary that were considered to have poor activity included cephalosporins, ciprofloxacin, and
trimethoprim/sulfamethoxazole. Moxifloxacin was classified as having variable activity against C. difficile
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patients receiving this agent in combination with other
antibiotics. There was no difference in the percentage of
inhibitory specimens for piperacillin/tazobactam admin-
istered as monotherapy versus in combination with
other antibiotics (7/10, 70 % versus 13/18, 72 %, respect-
ively; P = 1). Of the 19 stool specimens analyzed during
therapy with other inhibitory antibiotics, 7 (37 %) were
from patients receiving these agents in combination with
other antibiotics. There was no difference in the percent-
age of inhibitory specimens for these inhibitory agents
administered as monotherapy versus in combination
with other antibiotics (3/7, 43 % versus 8/12, 67 %,
respectively; P = 0.38).
For fecal suspensions of patients receiving inhibitory
antibiotics, fecal filtrates produced from inhibitory sus-
pensions consistently inhibited growth of C. difficile,
suggesting that inhibition was due to the presence of
antibiotics rather than bacteria. In contrast, a majority of
fecal filtrates produced from inhibitory suspensions of
patients receiving non-inhibitory antibiotics did not
inhibit growth of C. difficile.
Discussion
Our findings suggest that piperacillin/tazobactam, an
agent with activity against C. difficile that is excreted in
significant concentrations in bile [10], achieves sufficient
concentrations in the intestinal tract of many patients to
inhibit C. difficile colonization during treatment. Pa-
tients receiving piperacillin/tazobactam therapy were
infrequently colonized with C. difficile in comparison to
patients currently receiving agents lacking activity
against C. difficile. Moreover, 71 % of fecal suspensions
or filtrates from patients currently receiving piperacillin/
tazobactam were inhibitory to in vitro growth of C. diffi-
cile. These data are consistent with previous studies in
mice and in an in vitro human gut model [10, 19]. How-
ever, given previous evidence of significant inter-patient
variability in excretion of piperacillin and tazobactam in
stool [12, 13], we cannot exclude the possibility that the
infrequent colonization with C. difficile in piperacillin/
tazobactam-treated patients may be attributable to low
intestinal drug concentrations in some patients. In con-
junction with previous studies, our results provide evi-
dence that C. difficile colonization may be reduced by
formulary substitution of piperacillin/tazobactam for
cephalosporins.
We did not find that patients receiving other antibi-
otics with inhibitory activity against C. difficile (predom-
inantly carbapenems and ampicillin or amoxicillin) were
infrequently colonized with C. difficile in comparison to
those receiving non-inhibitory antibiotics. This finding
could potentially be related to low levels of biliary excre-
tion of some agents (e.g., imipenem-cilastatin, merope-
nem) [20], or to inactivation in the intestinal tract (e.g.,
ampicillin may be inactivated in the colon by beta-
lactamases) [21]. However, further studies are needed
because the number of patients evaluated was limited,
particularly for doxycycline and metronidazole.
We found relatively high rates of asymptomatic car-
riage of C. difficile in patients not on current antibiotics
but who had received antibiotic therapy within the past
90 days. Moreover, only 15 % of stool samples tested
from these patients were inhibitory to growth of C. diffi-
cile. These findings are consistent with recent studies
that demonstrate that antibiotic therapy may result in
prolonged disruption of the indigenous intestinal micro-
biota [22, 23]. Because piperacillin/tazobactam may
cause disruption of the indigenous microbiota that per-
sists after therapy, it should be appreciated that this
agent may have a biphasic effect on colonization with C.
Table 3 Prevalence Ratios of Predictors of Asymptomatic




95 % CI P value
Age (per year) 0.98 0.96, 1.01 0.18
Days from admission to culture (per day)
0–7 1.00 Reference
8–14 0.79 0.33, 1.89 0.6
15–21 1.25 0.44, 3.55 0.67
≥22 1.78 0.80, 3.97 0.16
CDI in the previous
90 days
4.21 2.11, 8.40 <0.001
Any antibiotics 0.93 0.48, 1.82 0.83
Antibiotics in the past
90 days
2.70 1.15, 6.33 0.02
Antibiotics in the past
30 days
2.20 1.03, 4.73 0.04
Inhibitory antibiotic activity
(vs. non-inhibitory activity)
against C. difficile (among
antibiotic users)








in past 90 days)
0.14 0.02, 0.99 0.05
Comorbidities
Heart disease 0.64 0.31, 1.32 0.23
Cancer 1.16 0.60, 2.27 0.65
Diabetes 0.75 0.38, 1.48 0.41
End stage renal disease 1.02 0.34, 3.10 0.97
Major surgery 0.86 0.40, 1.82 0.69
Spinal cord injury 1.56 0.60, 4.03 0.36
CI Confidence interval
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difficile (i.e., inhibition during therapy but promotion
after therapy during the period of recovery of the micro-
biota) [10]. Only 30 % of stool suspensions collected
during the 2 week period after discontinuation of pipera-
cillin/tazobactam were inhibitory to C. difficile and
asymptomatic carriage was common after discontinu-
ation of piperacillin/tazobactam (i.e., 43 % of carriers
who had received prior antibiotics had received pipera-
cillin/tazobactam).
Our study has several limitations. First, the study
population included only men, a majority of whom were
elderly. Additional studies are needed in other patient
populations. Second, we collected a single rectal culture
from many of the patients and therefore it is not known
if the positive cultures represent persistent versus transi-
ent colonization. Third, our study may underestimate
the true prevalence of asymptomatic carriage if many
patients carry spores at levels below the limit of detec-
tion of our methods (~2 log10colony-forming units/gm
of stool). Fourth, we did not examine susceptibility pat-
terns of C. difficile specific to our institution. Fifth, as
noted previously, more data is needed to evaluate the
potential for agents such as doxycycline and linezolid to
inhibit C. difficile colonization. Finally, we evaluated
whether inhibitory antibiotics were associated with
reduced asymptomatic carriage of C. difficile. Future
studies are needed to determine whether inhibitory anti-
biotics reduce the risk for infection during therapy.
Conclusions
Our findings demonstrate that piperacillin/tazobactam, an
agent with activity against C. difficile, achieves sufficient
concentrations in the intestinal tract of many patients to
inhibit C. difficile colonization during treatment. These
data suggest that C. difficile colonization may be reduced
with the use of piperacillin/tazobactam compared to other
regimens that are non-inhibitory to C. difficile. Fur-
ther studies are needed to determine if formulary
substitutions favoring use of piperacillin/tazobactam
over cephalosporins might have an impact on CDI
rates. Based on our findings, the potential impact of
such formulary substitutions may be limited by the
fact that piperacillin/tazobactam causes disruption of
the indigenous microbiota that persists after therapy
is discontinued.
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Fig. 2 In vitro growth of Clostridium difficile in stool suspensions of hospitalized patients, stratified by level of in vitro inhibitory activity against C.
difficile based on a modification of the classification of Owens et al. (1). A total of 141 stool specimens from 98 patients were analyzed (1–3 per
patient). Specimens were considered inhibitory if the concentration of C. difficile decreased or remained unchanged compared to the baseline
concentration. The non-inhibitory antibiotics that were administered at the time stool specimens were collected included ciprofloxacin (N = 6),
ceftriaxone (N = 5), and cephalexin (N = 1). The agents classified as other inhibitory antibiotics that were administered included imipenem
(N = 6), meropenem (N = 5), ertapenem (N = 6), linezolid (N = 4), ampicillin/sulbactam (N = 3), and metronidazole (N = 2). SE, standard error.
CFU, colony-forming unit
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